Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Declines By 59.4%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 342,200 shares, a decline of 59.4% from the March 15th total of 843,600 shares. Approximately 14.0% of the company’s shares are short sold. Based on an average trading volume of 841,800 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of CERo Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avantax Planning Partners Inc. grew its holdings in CERo Therapeutics by 89.9% in the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after purchasing an additional 1,224,021 shares during the period. Parallel Advisors LLC purchased a new position in shares of CERo Therapeutics in the 1st quarter worth $161,000. Finally, ARCH Venture Management LLC grew its position in CERo Therapeutics by 550.4% during the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock valued at $564,000 after acquiring an additional 7,949,265 shares during the period. Hedge funds and other institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Trading Down 2.6 %

Shares of CERo Therapeutics stock traded down $0.02 during trading hours on Wednesday, reaching $0.57. 231,304 shares of the company’s stock were exchanged, compared to its average volume of 443,247. CERo Therapeutics has a 52-week low of $0.55 and a 52-week high of $184.00. The company has a fifty day moving average of $1.23 and a 200-day moving average of $6.41.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.